Impact of genetic polymorphisms related to clopidogrel or acetylsalicylic acid pharmacology on clinical outcome in Chinese patients with symptomatic extracranial or intracranial stenosis.

PubWeight™: 0.76‹?›

🔗 View Article (PMID 27450232)

Published in Eur J Clin Pharmacol on July 23, 2016

Authors

Zhigang Zhao1,2,3, Xingang Li2,3, Shusen Sun4, Shenghui Mei2, Ning Ma5, Zhongrong Miao5, Ming Zhao6,7,8, Shiqi Peng9,10

Author Affiliations

1: Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Engineering Research Center of Endogenous Prophylactic of Ministry of Education of China, Beijing Laboratory of Biomedical Materials, College of Pharmaceutical Sciences, Capital Medical University, Beijing, People's Republic of China.
2: Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, Beijing, People's Republic of China.
3: Precision Medicine Research Center for Neurological Disorders, Beijing Tiantan Hospital, Capital Medical University, Beijing, People's Republic of China.
4: College of Pharmacy, Western New England University, Springfield, MA, 01109, USA.
5: Department of Interventional Neuroradiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, People's Republic of China.
6: Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Engineering Research Center of Endogenous Prophylactic of Ministry of Education of China, Beijing Laboratory of Biomedical Materials, College of Pharmaceutical Sciences, Capital Medical University, Beijing, People's Republic of China. mingzhao@bjmu.edu.cn.
7: Faculty of Biomedical Science and Environmental Biology, Kaohsiung Medical University, Kaohsiung, Taiwan. mingzhao@bjmu.edu.cn.
8: College of Pharmaceutical Sciences, Capital Medical University, No. 10 Xitoutiao, You An Men, Beijing, 100069, People's Republic of China. mingzhao@bjmu.edu.cn.
9: Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Engineering Research Center of Endogenous Prophylactic of Ministry of Education of China, Beijing Laboratory of Biomedical Materials, College of Pharmaceutical Sciences, Capital Medical University, Beijing, People's Republic of China. sqpeng@bjmu.edu.cn.
10: College of Pharmaceutical Sciences, Capital Medical University, No. 10 Xitoutiao, You An Men, Beijing, 100069, People's Republic of China. sqpeng@bjmu.edu.cn.

Articles citing this

Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel: Evidences and Perspectives. Int J Environ Res Public Health (2017) 0.78

Articles cited by this

Statistical significance for genomewide studies. Proc Natl Acad Sci U S A (2003) 88.64

Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med (2010) 17.57

Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med (2006) 11.72

Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med (2008) 8.39

Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA (2009) 6.80

Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol (1999) 6.62

Adjusting for multiple testing when reporting research results: the Bonferroni vs Holm methods. Am J Public Health (1996) 6.59

Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet (2008) 6.41

Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA (2010) 6.29

Long-term results of carotid stenting versus endarterectomy in high-risk patients. N Engl J Med (2008) 4.72

Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial. Lancet (2013) 4.57

Epidemiological transition of stroke in China: twenty-one-year observational study from the Sino-MONICA-Beijing Project. Stroke (2008) 3.81

Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med (2010) 3.32

Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos (2010) 3.06

Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol (1994) 3.05

Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin. Circulation (2012) 2.76

Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther (2013) 2.73

Predicting clopidogrel response using DNA samples linked to an electronic health record. Clin Pharmacol Ther (2011) 2.36

Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. J Am Coll Cardiol (2010) 2.03

Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation (2003) 1.91

Dual antiplatelet therapy with clopidogrel and aspirin after carotid artery stenting. J Invasive Cardiol (2001) 1.59

Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther (2006) 1.57

Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis. Am J Hum Genet (2008) 1.50

Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. Pharmacogenet Genomics (2007) 1.43

The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response. Pharmacogenet Genomics (2013) 1.19

Pharmacogenetics of aspirin resistance: a comprehensive systematic review. Br J Clin Pharmacol (2008) 1.18

Carboxylesterase 1 as a determinant of clopidogrel metabolism and activation. J Pharmacol Exp Ther (2012) 1.16

Epidemiological factors of stroke: a survey of the current status in china. J Stroke (2013) 1.12

Cytochromes P450 catalyze both steps of the major pathway of clopidogrel bioactivation, whereas paraoxonase catalyzes the formation of a minor thiol metabolite isomer. Chem Res Toxicol (2011) 1.06

Genetic variation in PEAR1 is associated with platelet aggregation and cardiovascular outcomes. Circ Cardiovasc Genet (2013) 0.99

Meta-analysis of cytochrome P450 2C19 polymorphism and risk of adverse clinical outcomes among coronary artery disease patients of different ethnic groups treated with clopidogrel. Am J Cardiol (2012) 0.98

Aspirin resistance: effect of clinical, biochemical and genetic factors. Pharmacol Ther (2011) 0.97

Gene sequence variations of the platelet P2Y12 receptor are associated with coronary artery disease. BMC Med Genet (2007) 0.91

ABCB1 C3435T polymorphism and response to clopidogrel treatment in coronary artery disease (CAD) patients: a meta-analysis. PLoS One (2012) 0.91

Mechanisms of aspirin resistance. Pharmacol Ther (2013) 0.91

Carboxylesterase 1 c.428G>A single nucleotide variation increases the antiplatelet effects of clopidogrel by reducing its hydrolysis in humans. Clin Pharmacol Ther (2015) 0.88

Association between polymorphisms of eNOS and GPx-1 genes, activity of free-radical processes and in-stent restenosis. Mol Cell Biochem (2012) 0.87

CYP2C19 genotype has a greater effect on adverse cardiovascular outcomes following percutaneous coronary intervention and in Asian populations treated with clopidogrel: a meta-analysis. Circ Cardiovasc Genet (2014) 0.84

Anti-platelet therapy and aspirin resistance - clinically and chemically relevant? Curr Med Chem (2010) 0.84

Aspirin resistance: Where are we now? Anadolu Kardiyol Derg (2013) 0.83

Enhanced clopidogrel responsiveness in smokers: smokers' paradox is dependent on cytochrome P450 CYP1A2 status. Arterioscler Thromb Vasc Biol (2010) 0.81

Role of glycoprotein Ia gene polymorphisms in determining platelet function in myocardial infarction patients undergoing percutaneous coronary intervention on dual antiplatelet treatment. Atherosclerosis (2006) 0.81

Besides CYP2C19, PON1 genetic variant influences post-clopidogrel platelet reactivity in Chinese patients. Int J Cardiol (2012) 0.80

C3435T polymorphism of the ABCB1 gene is associated with poor clopidogrel responsiveness in a Mexican population undergoing percutaneous coronary intervention. Thromb Res (2015) 0.80

Aspirin resistance in cardiovascular disease. BMJ (2008) 0.79

Influence of Diabetes Mellitus and Cigarette Smoking on Variability of the Clopidogrel-Induced Antiplatelet Effect and Efficacy of Active Management of the Target P2Y12 Reaction Unit Range in Patients Undergoing Neurointerventional Procedures. J Stroke Cerebrovasc Dis (2015) 0.78

Aspirin resistance: does it exist? Semin Thromb Hemost (2007) 0.78

Patients with both CYP2C19 loss-of-function allele and peripheral endothelial dysfunction are significantly correlated with adverse cardiovascular events following coronary stent implantation. J Cardiol (2015) 0.78

Gene polymorphism of cytochrome P450 2C19*2 and clopidogrel resistance reflected by platelet function assays: a meta-analysis. Eur J Clin Pharmacol (2014) 0.78

Clopidogrel Resistance Increases Rate of Recurrent Stroke and Other Vascular Events in Chinese Population. J Stroke Cerebrovasc Dis (2016) 0.77

CYP2C19 metabolizer status and clopidogrel efficacy in the Secondary Prevention of Small Subcortical Strokes (SPS3) study. J Am Heart Assoc (2015) 0.77

Association of PON1, P2Y12 and COX1 with Recurrent Ischemic Events in Patients with Extracranial or Intracranial Stenting. PLoS One (2016) 0.77

Omeprazole, pantoprazole, and CYP2C19 effects on clopidogrel pharmacokinetic-pharmacodynamic relationships in stable coronary artery disease patients. Eur J Clin Pharmacol (2015) 0.76

Cardiovascular risk among patients on clopidogrel anti-platelet therapy after placement of drug-eluting stents is modified by genetic variants in both the CYP2C19 and ABCB1 genes. Thromb Haemost (2013) 0.75

Influence of smoking on the antiplatelet effect of clopidogrel differs according to clopidogrel dose: Insights from the GRAVITAS trial. Catheter Cardiovasc Interv (2016) 0.75

Recurrent Stroke while on Antiplatelet Therapy. Neurol Clin (2015) 0.75

The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease. Thromb Haemost (2014) 0.75